New strategies in the modulation of fatty acid oxidation as a treatment for obesity by Herrero Rodríguez, Laura et al.
 Transworld Research Network  
   37/661 (2), Fort P.O. 
   Trivandrum-695 023  
Kerala, India 
 
 
Recent Advances in Pharmaceutical Sciences III, 2013: 77-89 ISBN: 978-81-7895-605-3                   
Editors: Diego Muñoz-Torrero, Amparo Cortés and Eduardo L. Mariño 
 
5. New strategies in the modulation  
of fatty acid oxidation as a treatment  
for obesity   
 
Laura Herrero1, Paula Mera1, Josep M. Orellana-Gavaldà1 
Chandrashekaran Gurunathan1, Maria Ida Malandrino1, Joan Francesc Mir1 
Kamil Makowski1,2, Macarena Pozo1, Maria del Mar Arasa1, Xavier Ariza2 
Guillermina Asins1, Jordi García2, Fausto G. Hegardt1 and Dolors Serra1 
1Department of Biochemistry and Molecular Biology, Facultat de Farmàcia, IBUB (Institut de 
Biomedicina de la Universitat de Barcelona), CIBERobn (CIBER Fisiopatología de la Obesidad y 
la Nutrición, Instituto de Investigaciones Biomédicas Carlos III), Universitat de Barcelona, Av. 
Diagonal 643, Barcelona, 08028, Spain; 2Department of Organic Chemistry, Facultat de 
Química, IBUB, CIBERobn, Universitat de Barcelona, Spain 
 
Abstract. Strategies that enhance fat degradation or reduce caloric 
food intake could be considered therapeutic interventions to reduce not 
only obesity, but also its associated disorders. The enzyme carnitine 
palmitoyltransferase 1 (CPT1) is the critical rate-determining regulator 
of fatty acid oxidation (FAO) and might play a key role in increasing 
energy expenditure and controlling food intake. Our group has shown 
that mice overexpressing CPT1 in liver are protected from weight gain, 
the development of obesity and insulin resistance. Regarding food 
intake control, we observed that the pharmacological inhibition of 
CPT1 in rat hypothalamus decreased food intake and body weight. 
This suggests that modulation of CPT1 activity and the oxidation of 
fatty acids in various tissues can be crucial for the potential treatment 
of obesity and associated pathologies.   
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Introduction 
 
 Obesity and its associated metabolic disorders, such as insulin resistance, 
type 2 diabetes, cardiovascular disease and other severe pathologies, are one of 
the most serious public health concerns of the twenty-first century. There are 
more than 500 million obese people worldwide and, more importantly, 
overweight and obesity are the fifth leading risk for global deaths [1]. In the last 
few years, a concerted effort has been made to understand the pathophysiology of 
obesity and particularly its association with insulin resistance. Various 
mechanisms have emerged in the past two decades to elucidate this causal 
relationship. i) Ectopic fat deposition: during obesity the capacity of adipose 
tissue to expand in order to store excess fat fails, resulting in lipid spillover to 
peripheral organs such as liver, skeletal muscle and pancreas [2,3]. This incorrect 
lipid accumulation creates a lipotoxic environment, mainly mediated by 
diacylglycerols (DAG), that blocks correct glucose transport and insulin signaling 
[4]. ii) Inflammation: the excess of lipids accumulated in the adipose tissue 
during obesity causes adipocyte hypoxia [5], endoplasmic reticulum (ER) stress 
[6], cell death, and finally FA spillover [4]. These events lead to the recruitment 
and activation of immune cells in the adipose tissue. Obese adipocytes and 
infiltrated immune cells secrete many inflammatory cytokines that promote a 
proinflammatory state that contributes to local and systemic insulin resistance 
[7,8]. iii) Food intake: the central nervous system, specifically the hypothalamus, 
is extremely important in obesity-induced pathologies, since it plays a major role 
in the control of food intake and the regulation of body weight. In fact, leptin, an 
adipocyte-secreted hormone, acts on the hypothalamus to inhibit food intake and 
control body weight and is essential in the interaction between the brain and other 
organs in obesity-related disorders [9,10]. 
 Every therapeutic strategy to combat obesity is focused on increasing 
energy expenditure through regular exercise and/or reducing energy intake. 
However, the maintenance of lifestyle modifications for long periods is difficult 
and challenging. All the anti-obesity drugs on the market approach obesity by 
aiming to limit energy intake. Nonetheless, the list of food intake-limiting drugs 
withdrawn from the market for safety reasons seems to be constantly 
increasing: fenfluramine, desfenfluramine, sibutramine and rimonabant [11]. 
Currently, only orlistat and lorcaserin have an approved clinical indication for 
obesity treatment, but not worldwide, since the EMA is still studying the 
approval of the latter [12]. Owing to the pandemic of obesity-related diseases, 
there is a need for a wider range of drugs with different mechanisms and           
a safer profile to optimize and individualize obesity management therapies.              
The development of different strategies, such as those designed to increase lipid 
mobilization and oxidation, has become an imperative. 
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 Long chain fatty acid oxidation plays a key role in the development of 
obesity and occurs in mitochondria. Lipid transport into the mitochondria is 
mediated by the carnitine palmitoyltransferase (CPT) system [13], which is 
comprised of CPT1, acylcarnitine translocase and CPT2. The first protein, CPT1, 
catalyzes the rate-limiting step in mitochondrial fatty acid oxidation (FAO), since 
it can be regulated by changes in malonyl-CoA levels. These levels are controlled 
by acetyl-CoA carboxylase (ACC), which controls malonyl-CoA synthesis, and 
malonyl-CoA decarboxylase (MCD), which catalyzes malonyl-CoA degradation 
[13]. Together, these components act as a metabolic network that senses the cell’s 
energy state. Once long chain fatty acids have been degraded to acetyl-CoA in the 
mitochondria, they are transformed into ATP through the Krebs cycle and 
oxidative phosphorylation, in which ATP molecules are made up from the 
derived NADH and FADH2 energy used to create the electrochemical gradient 
needed by ATP synthase [14]. 
 Mammal tissues express three isoforms of CPT1: CPT1A, which was 
originally discovered in liver but is present almost ubiquitously [15], CPT1B 
that is present in muscle and heart [16], and CPT1C, the latest isoform to be 
discovered, which is expressed mainly in the brain [17]. 
 Our research indicates that the modulation of mitochondrial bioenergetics, 
and especially FAO, is a good target for anti-obesity therapy. Our strategy is 
based on two main interventions: one in peripheral tissues such as muscle and 
liver, and the other at central level in the hypothalamus. In peripheral tissues, 
overexpression of the CPT1A gene seemed to be a suitable approach, because 
presumably the effects of this intervention would reduce the intracellular lipid 
content, and lead to a general improvement in cellular metabolism. Furthermore, 
we have produced a M593S CPT1A cDNA rat mutant (CPT1AM), whose 
translated protein is active, but totally insensitive to malonyl-CoA inhibition [18]. 
Therefore, overexpression of CPT1AM would disconnect glucose metabolism, 
which increases malonyl-CoA levels, from accelerated fatty acid catalysis.               
Thus, the reduction in cellular lipids would be produced much more efficiently. 
At central level, our approach is based on the inhibition of CPT1 activity, which 
is involved in the signaling pathway that controls food intake.  
 
1. The enhancement of mitochondrial FAO in liver ameliorates 
insulin resistance and prevents obesity induced by a high-fat 
diet 
 
 In liver, conditions associated with prolonged energy excess or impaired 
FA metabolism lead to the accumulation of considerable amounts of lipids. 
This triggers the development of non-alcoholic fatty liver disease (NAFLD), 
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which involves a series of liver abnormalities. NAFLD produces an abnormal 
accumulation of lipids and inflammation. It also renders insulin unable to 
control hepatic gluconeogenesis. This is usually the beginning of diabetes, 
but episodes of steatohepatitis, cirrhosis and hepatocellular carcinoma are 
common at later stages of development [19-21]. 
  Considering that NAFLD is ultimately the result of an imbalance 
between lipid inputs and outputs in the hepatocytes, any intervention that 
stimulates hepatic FAO should result in reduced hepatic fat accumulation. 
Several pharmacological approaches that activate FAO have been reported 
using PPAR [20,22] and AMPK [23,24] agonists and ACC antagonists 
[25,26]. More interesting are studies in rodents to decrease steatosis by 
increasing FAO specifically in liver. In these studies, short-term modulation 
of ACC [27] and MCD [28] gene expression produced a reduction in 
malonyl-CoA levels and an increase in FAO. In addition, a decrease in 
hepatic TAG content and insulin resistance was observed in obese animals. 
However, the notion that these target genes are implicated in other metabolic 
pathways raises the question of their effectiveness in long-term treatments. 
 Taking into account that the main factor that increases FAO is the 
mitochondrial membrane enzyme CPT1A, which is the critical rate-determining 
regulator of beta-oxidation, overexpression of the CPT1A gene seemed to be 
a suitable approach, because presumably the effects of this intervention 
would reduce the lipid content, and lead to a general improvement in hepatic 
metabolism. Hepatic overexpression of CPT1A mediated by adenovirus has 
been performed by Stefanovic-Racic et al. [29] in obese rats. They observed 
a slight increase in FAO that led to a reduction in hepatic TAG levels, but did 
not reveal any improvement in insulin sensitivity. The moderate effect              
might be due to the increased malonyl-CoA levels induced by a high-fat diet 
(HFD), which could limit in vivo CPT1A activity, in spite of the CPT1A 
overexpression.  
 To avoid malonyl-CoA inhibition, we generated a mutant CPT1A 
isoform, CPT1AM [18], that is insensitive to malonyl-CoA. Results published by 
our group confirm in the pancreatic cell line INS-1 [30] and muscle cell line 
L6E9 [31] that adenovirus-mediated overexpression of CPT1AM is more 
efficient at increasing mitochondrial FAO. Furthermore, overexpression of 
CPT1AM in L6E9 cells produces a 2-fold increase in palmitate oxidation, 
and decreases its esterification into cellular lipids. Similar results were 
obtained in hepatocyte primary culture by [32] and our group (Fig. 1). 
Adenovirus-mediated CPT1AM overexpression produced higher oleate 
oxidation than the CPT1A wild type isoform and a higher reduction in 
intracellular TAG content when hepatocytes where incubated in the presence 
of palmitate (Fig. 1).  
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Figure 1. CPT1 overexpression reduced intracellular TAG content. Rat hepatocytes 
were transduced for 24 h. After this time, cells were treated with palmitate for 4 h. 
Lipids were extracted and TAG were measured using the Cromatest Triglyceride kit. 
*P < 0.05 vs. Lac Z – Palmitate, &P < 0.05 vs. Lac Z + Palmitate.  
 
 In addition to in vitro studies, we performed in vivo experiments in mice 
fed with HFD [33]. We achieved hepatic gene transfer of CPT1A and the 
permanent active form CPT1AM to obese mice by injecting adeno-associated 
viruses (AAV) into the tail vein. The use of AAV-CPT1A and AAV-
CPT1AM led to long-term liver-selective gene transfer that allowed us to 
evaluate the metabolic impact and underlying mechanisms of increased FAO 
in diet-induced and genetically obese mice. In these studies, we observed that 
HFD CPT1A- and CPT1AM-expressing mice showed a general improvement 
in hepatic glucose and lipid metabolism as a consequence of increased 
hepatic fatty acid flux through mitochondria. In turn, this prevented 
intracellular lipid accumulation in liver (Fig. 2) and ROS production and 
rescued the impaired hepatic insulin signal, especially in CPT1AM-
expressing mice (Fig. 3). It seems that liver can deal with an increased flux of 
FA into the mitochondria, thus escaping from liver injury. This is due to the 
ability of liver to flip the balance from complete oxidation to ketone body 
production [34]. The ketone bodies produced by enhanced FAO are easily 
consumed by other tissues. This increases the flux of carbons from liver               
to other organs (Fig. 3). In addition, enhanced mitochondrial FAO in liver 
reduced the lipid accumulation in white adipose tissue and prevented the 
increase of body weight in these HFD mice. The impaired insulin signaling in 
tissues such as muscle and white adipose tissue was also ameliorated. These 
results have been further confirmed by Monsenego et al. [35].  
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Figure 2. Liver histology in GFP, CPT1A- and CPT1AM-expressing mice. Liver 
histological sections (hematoxylin and eosin staining) from representative 29-week-old 
GFP control mice and GFP-, CPT1A- and CPT1AM-expressing HFD littermates.  
 
 In genetically obese db/db mice expressing CPT1AM we also observed 
an improvement in the hyperglycemia and hyperinsulinemia that these 
animals suffer. Taken together, these results highlight an increase in hepatic 
CPT1AM as a new strategy for the treatment of NAFLD/NASH pathologies 
and obesity (Fig. 3).  
 Another strategy has been proposed to improve mainly glucose 
homeostasis in HFD-treated mice. This approach is based on the 
administration of CPT1 inhibitors. Although this treatment reduced hepatic 
gluconeogenesis, it also caused hepatic steatosis in HFD-treated mice 
[36,37]. This side-effect has discarded the development of other CPT1 
systemic inhibitors, such as etomoxir and 2-tetradecylglycidic acid, as a 
therapeutic tool. Taken together, these data support the idea that any strategy 
that can switch liver FA’s fate from esterification towards oxidation has a 
beneficial effect on liver and on the whole body.  
 Recently, a new hepatic factor, fibroblast growth factor 21 (FGF21), has 
emerged as a key regulator in FAO and ketogenic activation. FGF21 is 
upregulated in liver during fasting [38,39] and has been increasingly 
indicated as a potential therapeutic agent in obesity-induced insulin-resistant 
states [40]. 
New strategies in the modulation of fatty acid oxidation as a treatment for obesity   83 
 
 
Figure 3. Effects of enhanced FAO in fatty liver. (a) Obesity increases fatty acid (FA) 
uptake, TAG (triacylglycerides), DAG (diacylglycerol), ceramides and other lipid 
derivatives that may inhibit insulin signaling. FA accumulation induces mitochondrial 
dysfunction and increased ROS production, oxidative stress and inflammation that 
could also disrupt insulin signaling. (b) Enhancing FAO by the overexpression of 
CPT1AM increases the production of ketone bodies, ATP and CO2. The reduction of 
lipid content reestablishes lipid metabolism and insulin signaling. It also decreases 
inflammation and ROS production. FAO: fatty acid oxidation; GSK: glycogen 
synthase kinase-3; GS: glycogen synthase; IRS-1/2: insulin receptor substrate; LCFA: 
long chain fatty acids; PKC: protein kinase C; PI3K: phosphoinositide 3-kinase; 
PDK1: phosphoinositide-dependent kinase-1; PKB: protein kinase B; ROS: reactive 
oxygen species; TCA: tricarboxylic acid cycle; TNFα: tumor necrosis factor; NCD 
normal control diet. 
 
2. Inhibition of CPT1 in the hypothalamus reduces food 
intake and body weight 
 
 The central nervous system (CNS) plays a major role in the evaluation 
and control of energy homeostasis. Blood concentrations of glucose and              
fatty acids are sensed by neurons of the hypothalamus, which adjusts            
feeding behavior by altering the expression of specific neuropeptides and 
neurotransmitters. It is now well established that hypothalamic lipid 
metabolism participates in this action of the hypothalamus and is linked to 
molecular mechanisms by which hormones and nutrients exert their central 
effect on food intake [41]. Recently, much effort has been invested in 
designing new anti-obesity drugs and modulating fatty acid metabolism to 
inhibit food intake. 
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  Both malonyl-CoA, the first intermediate in de novo lipogenesis, and 
LCFA-CoAs have been proposed as satiety molecular signals in the 
hypothalamus [42-45]. For this reason, drugs designed to raise hypothalamic 
concentrations of these molecules are good candidates for the treatment of 
food intake disorders. The enzyme fatty acid synthase (FAS) catalyzes the 
synthesis of palmitate from acetyl-CoA and malonyl-CoA. It has been 
reported that FAS inhibition in the hypothalamus suppresses food intake 
through the accumulation of malonyl-CoA [46,47]. C75 is a synthetic inhibitor 
of FAS and has been proposed as an anti-obesity agent, since its administration 
decreases appetite and body weight in rodents [48]. However, the exact 
molecular mechanism underlying C75-derived anorexia is not completely 
understood. Firstly, some evidence showed a disconnection between C75-
induced hypophagia and FAS inhibition in the hypothalamus [49]. Secondly, 
the inhibition of FAS by C75 produces an accumulation of malonyl-CoA that 
is difficult to reconcile with the activation of CPT1 reported by others authors 
[50,51]. Finally, our group previously reported that the Coenzyme A adduct 
of C75 (C75-CoA) is a potent inhibitor of CPT1 [52] (Fig. 4). Taking these 
data into account, further research is needed to clarify whether C75-induced 
hypophagia is directly related to hypothalamic inhibition of FAS, CPT1 or 
both enzymes.  
 It has been stated that pharmacological and genetic inhibition of CPT1 in 
the hypothalamus reduces food intake [53,54]. Rossetti and co-workers 
demonstrated that genetic inhibition of the isoform CPT1A in the mediobasal 
hypothalamus not only reduced feeding in rats, but also diminished hepatic 
gluconeogenesis. Similar results were obtained with tetradecylglycidic acid 
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Figure 4. Effect of C75-CoA on the activity of yeast-expressed CPT1A. Mitochondrial 
extracts from yeast expressing CPT1A were preincubated with increasing concentrations 
of C75-CoA. CPT1A activity was measured, and data are expressed relative to control 
values in the absence of C75-CoA (100%).  
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and the compound ST1326, a synthetic CPT1 inhibitor. The observed 
anorexia was accompanied by a significant increase of LCFA-CoAs in the 
hypothalamus. The same authors demonstrated that central injection of oleic 
acid produced a reduction in food consumption, due to the downregulation of 
orexigenic neuropeptides in the hypothalamus [44]. Based on these results, 
our group attempted to explain the anorectic effects of C75 in terms of                
its inhibitory action on hypothalamic CPT1. We first demonstrated that, 
following its central administration, C75 is converted to C75-CoA in the 
hypothalamus [55]. In addition, central C75 administration produced a 
significant inhibition of CPT1 activity in the hypothalamus [55] (Fig. 5a). 
Furthermore, central injection of etomoxir, a well-known CPT1 inhibitor, 
also decreased feeding and reduced body weight in rats (Fig. 5b and c). 
Together, these data suggested that hypothalamic CPT1 inhibition could, at 
least partly, mediate the anorectic effect of C75.  
 We propose that the direct in vivo effect of C75-CoA on hypothalamic 
CPT1 explains the inhibition of CPT1 activity and the subsequent reduction 
in food intake. However, FAS could also be inhibited by C75 in the 
hypothalamus. Therefore, malonyl-CoA could be in excess and inhibit CPT1, 
together with C75-CoA (Fig. 6).  
 Despite the aforementioned results, further research is needed to unravel 
the exact mechanism by which CPT1 inhibition affects the expression of 
hypothalamic neuropeptides and, consequently, feeding behavior. Our group 
is currently working on two main research lines: the clarification of the           
exact role of hypothalamic CPT1 in the regulation of appetite and C75-derived 
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Figure 5. Central nervous system administration of C75 inhibits CPT1 activity and 
decreases food intake and body weight. (a) CPT1 activity after intracerebroventricular 
(i.c.v.) injection of C75 (control animals, RPMI medium). (b) Food intake measured 
in rats at 1, 2, 4 and 22 h after i.c.v. injection of C75, etomoxir and control (RPMI 
medium). (c) Body weight measured in rats at 22 h after i.c.v. injection of C75, 
etomoxir and control (RPMI medium). * P < 0.05. 
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Figure 6. Model of action of C75 on hypothalamic fatty acid metabolism. The energy 
balance is monitored by the hypothalamus. The accumulation of malonyl-CoA due to 
FAS-inhibition by C75 leads to a reduction in CPT1 activity. This would increase the 
cytosolic pool of LCFA-CoA and thus decrease food intake. In addition, C75 may 
inhibit AMPK, resulting in activation of ACC and a consequent increase in malonyl-
CoA levels [56]. Here, we have shown that C75 is converted into C75-CoA in the 
hypothalamus, which contributes to the direct inhibition of CPT1. Our experiments 
also demonstrate that other CPT1 inhibitors such as etomoxir produce similar effects 
of decreasing food intake. However, AMPK-activators lead to ACC inactivation, 
which reduces malonyl-CoA levels and CPT1 inhibition. Thus, increased FAO 
reduces LCFA-CoAs and promotes food intake. 
 
anorexia, and the design and synthesis of new CPT1 inhibitors as a first step 
in the development of new anti-obesity drugs. 
 
3. Conclusion 
 
 There is general agreement that we need to look for new treatments to fight 
against the current epidemic of obesity and related diseases. Dietary 
modification and regular exercise are two classical and very effective strategies 
for decreasing nutrient overload. However, long-term maintenance of these 
strategies is difficult and challenging. Thus, new therapeutic strategies are 
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needed to reduce the lipid burden and increase energy expenditure. 
Alternatively, new drugs should be developed to modulate eating behavior.   
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